Vifor Pharma and Akebia Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval
Go back to Vifor Pharma and Akebia Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval| AKEBIA THERAPEUTICS (NASDAQ: AKBA) | Delayed: 0.92 +0.02 (2.22%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.90 | 52 Week High | $13.20 | |||
| Open | $0.89 | 52 Week Low | $7.00 | |||
| Day High | $0.96 | P/E | N/A | |||
| Day Low | $0.88 | EPS | $0.00 | |||
| Volume | 5,249,279 | |||||
